Power3 Medical Products, Inc (PWRME)
Alzheimer’s disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person’s ability to carry out daily activities.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
Alzheimer’s disease begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD (Alzheimer’s disease) may have trouble remembering things that happened recently or names of people they know. Over time, symptoms get worse. People may not recognize family members or have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them.
Alzheimer’s disease usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease.
Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro�, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:
1) Breast Cancer 5) Chemotherapeutic Drug Resistance
2) Alzheimer’s Disease 6) Leukemia
3) ALS (Lou Gehrig’s Disease) 7) Gastrointestinal Disease
4) Parkinson’s Disease 8)Metabolic Syndrome
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com
Majestic Gold Corp. (MJS.V)
The most important industrial use of gold is in the manufacture of electronics. Solid state electronic devices use very low voltages and currents which are easily interrupted by corrosion or tarnish at the contact points. Gold is the highly efficient conductor that can carry these tiny currents and remain free of corrosion. Electronic components made with gold are highly reliable. Gold is used in connectors, switch and relay contacts, soldered joints, connecting wires and connection strips.
Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.
Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company’s flagship Song Jiagou project.
The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tonnes per day and progressively move upwards towards full capacity of 6,000 tonnes per day once the mill is running at optimal efficiency.
Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.
For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net
Avery Dennison Corporation (NYSE:AVY) announced that Dean A. Scarborough, chairman, president and CEO, will present at 8:45 a.m. Central Time on May 10, 2011, at Robert W. Baird & Co.’s 2011 Growth Stock Conference in Chicago, Illinois. The presentation will be webcast live on Avery Dennison’s Investor Relations website (www.investors.averydennison.com). A replay will be available following the event. Institutional investors who would like a meeting with management should contact their R.W. Baird representative or Priscilla Silva of Avery Dennison at (626) 304-2165.
Avery Dennison Corporation produces pressure-sensitive materials, office products, tickets, tags, labels, and other converted products. The company operates in three segments: Pressure-sensitive Materials, Retail Information Services, and Office and Consumer Products.
Fidelity National Financial, Inc. (NYSE:FNF) a leading provider of title insurance, mortgage services, specialty insurance and information services, announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable June 30, 2011, to stockholders of record as of June 16, 2011.
Fidelity National Financial, Inc., through its subsidiaries, provides title insurance, specialty insurance, claims management services, and information services in the United States.
Knight Transportation Inc. (NYSE:KNX) reported revenue and earnings for the first quarter ended March 31, 2011. For the quarter, total revenue increased 12.5% to $186.5 million from $165.7 million for the same quarter of 2010. Revenue before fuel surcharge increased 7.3% to $150.5 million compared to $140.3 million in the first quarter of 2010. Net income decreased to $9.9 million in the first quarter from $12.3 million for the same quarter of 2010 and net income per diluted share was $0.12, compared to $0.15 for the same quarter of 2010.
Knight Transportation, Inc., together with its subsidiaries, operates as a short to medium-haul truckload carrier of general commodities in the United States. The company was founded in 1989 and is headquartered in Phoenix, Arizona.
No comments:
Post a Comment